4588.T
Oncolys BioPharma Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 6,300.00
+8.62%Sep 17, 2026, 06:41 UTC
Japanese stocks rose on September 17, with Kubotek leading the Tokyo Stock Exchange Standard market gainers at a 29.6% increase.
Source:Sep 16, 2026, 06:41 UTC
Shares of Oncolys BioPharma fell 9.2% on September 16, 2026.
Source:Sep 7, 2026, 01:27 UTC
Oncolys BioPharma disclosed that it received preliminary information from a trading financial institution that it meets both TOPIX new inclusion requirements: annual trading value turnover ratio of 0.2 or higher and cumulative float market cap ratio within the top 96%.
Source:Sep 1, 2026, 06:40 UTC
On September 1, 2026, four stocks hit limit-up and four hit limit-down at the close on the Tokyo Stock Exchange, including Brain's Technology, DeltaFly Pharma, Asterisk, and others.
Source:Aug 27, 2026, 22:30 UTC
Oncolys BioPharma announced that results of a Phase 2a clinical trial of LINE-1 inhibitor senzavudine for progressive supranuclear palsy were published in the overseas medical journal 'Movement Disorders'.
Aug 12, 2026, 05:57 UTC
Oncolys BioPharma announced that its cancer virus drug Telomelysin for esophageal cancer has been listed for insurance coverage and will be sold starting August 21, 2026.